Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial

a Mean ACQ-5 scores, b geometric mean blood eosinophil counts including proportions of subjects with mean ACQ-5 score？≥？1.5/<？1.5 and blood eosinophil counts？≥？150/<？150 cells/μL. Mean ACQ-5 scores and geometric blood eosinophil counts were measured during the open label period and following treatment discontinuation. Error bars represent 95% confidence interval. Reference line for a at a mean ACQ-5 score of 1.5. Reference line for b at a geometric mean blood eosinophil count of 150 cells/μL. ACQ-5 Asthma Control Questionnaire-5, SC subcutaneou